Boston Biomedical, Inc. and AiRNA Pharmaceuticals, Inc. have announced that asymmetrical interfering RNA (aiRNA), a new fundamental RNAi technology discovered by the companies, is being published in the December issue of Nature Biotechnology. The publication titled “Asymmetric RNA Duplexes Mediate RNA Interference in Mammalian Cells” highlights that the smaller 15 bp aiRNA can target a variety of genes with superior efficiency than the standard 19-21 bp siRNA. Furthermore, the new aiRNA structure can target genes more selectively with significantly less off-target effects than the standard 19-21 bp siRNA.